Oncometabolites, DNA Repair, and Cancer Therapy

Contact rachel.taylor@oncology.ox.ac.uk for team link to this talk

Peter Glazer is the Robert E. Hunter Professor of Therapeutic Radiology, Professor of Genetics, and Chair of the Department of Therapeutic Radiology at Yale University. Glazer received his undergraduate education at Harvard (BA), graduate education at the University of Oxford (M.Sc.) and Yale (M.D. and Ph.D.), and residency training in radiation oncology at Yale. He has had longstanding research interests in tumour hypoxia, DNA repair, cancer therapy and gene editing, with over 200 primary research publications and more than 20 patents. Dr. Glazer recently discovered that human malignancies with mutations in isocitrate dehydrogenase (IDH) and other Krebs cycle genes have previously unsuspected DNA repair defects and vulnerability to PARP inhibitors and other targeted agents, changing the paradigm by which these tumours should be treated. Overall, his research has led directly to more than six new clinical trials for cancer, two investigational new drug applications, and the founding of three biotechnology companies. Glazer has conducted NIH funded research programs for over 25 years, recently receiving an Outstanding Investigator Award from the National Cancer Institute. He has also received research awards from the American Society for Photobiology, the Radiation Research Society, the Leukaemia & Lymphoma Society and the John Yuhas Award from the University of Pennsylvania School of Medicine. He is an elected member of the Association of American Physicians.